Rezdiffra Pregnancy and Lactation Registry, NCT07541469

This document adds a new observational registry study (NCT07541469) to ClinicalTrials.gov. The study records Rezdiffra as both the intervention and the focus of a pregnancy/lactation exposure cohort, with no active enrollment criteria or compliance deadlines described in the registration entry.

Affected parties — pharmaceutical companies, clinical investigators, and healthcare providers — should note this registry as a postmarketing safety surveillance mechanism. The study generates no immediate regulatory obligations but may inform future labeling or safety communications for Rezdiffra as data accumulates.